Compare Ginkgo Bioworks Holdings Inc (DNA) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Garmin Ltd. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $8.99 (market cap $590.53M), while Garmin Ltd. trades at $242.3 (market cap $46.55B). The key difference: Garmin Ltd. is far larger — about 78.8× Ginkgo Bioworks Holdings Inc's market cap, and Garmin Ltd. pays a 1.74% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | GRMN | |
|---|---|---|
Market Cap | $590.53M | $46.55B |
Sector | Health | Technology |
52-Week High | $16.14 | $267.52 |
52-Week Low | $5.48 | $187.10 |
Enterprise Value | $627.78M | $44.02B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Garmin (GRMN) trades at $243.61, up 0.21% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth, reaching $7.25B in 2025, with a net income margin of 23.26%. Recent product launches, including AXIS flight displays and LiveScope 2 sonar, highlight innovation. The stock is near its pivot point of $243, with support at $242 and resistance at $245.
Outlook remains positive with a consensus price target of $282.67, implying 16% upside. Risks include competitive pressures in consumer electronics and aviation markets. Analyst sentiment is mixed, with 74% hold ratings, but earnings beats in recent quarters support growth trajectory. Dividend payments provide shareholder returns, with the next payment scheduled for September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
